placebo for the PF-06651600 50mg clinical trials

B7981040 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO

This study is testing a new medicine, Ritlecitinib, for vitiligo, a skin condition where you lose skin colour. It aims to see how well it works and if it's safe for adults and teenagers.